Research Article
Overexpression of Pleckstrin Homology Domain-Containing Family A Member 4 Is Correlated with Poor Prognostic Outcomes and Immune Infiltration in Lower-Grade Glioma
Figure 1
Role of PLEKHA4 in pan-cancer. (a) The mRNA expression of PLEKHA4 between tumour and normal control tissues was assessed from TCGA database.(b) Correlation of PLEKHA4 with the immune-related scores in human solid cancers from TCGA database.(c–h) The PELKHA4 expression levels in LGG and normal brain tissues from the GSE109857, GSE147352, GSE4290, GSE16011, Rembrandt set, and TCGA-GTEX datasets.(i) Univariate Cox regression analysis estimating prognostic value (OS/PFI/DSS) of PLEKHA4 in different cancer types from TCGA database. The length of horizontal line represents the 95% CI for each group. The vertical dotted line represents . indicates overexpression. PLEKHA4 is an unfavourable prognostic biomarker. ACC: adrenocortical carcinoma; BLCA: bladder urothelial carcinoma; BRCA: breast invasive carcinoma; CESC: cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL: cholangiocarcinoma; COAD: colon adenocarcinoma; DLBC: lymphoid neoplasm diffuse large B cell lymphoma; ESCA: esophageal carcinoma; GBM: glioblastoma multiforme; HNSC: head and neck squamous cell carcinoma; KICH: kidney chromophobe; KIRC: kidney renal clear cell carcinoma; KIRP: kidney renal papillary cell carcinoma; LAML: acute myeloid leukemia; LGG: brain lower grade glioma; LIHC: liver hepatocellular carcinoma; LUAD: lung adenocarcinoma; LUSC: lung squamous cell carcinoma; MESO: mesothelioma; OV: ovarian serous cystadenocarcinoma; PAAD: pancreatic adenocarcinoma; PCPG: pheochromocytoma and paraganglioma; PRAD: prostate adenocarcinoma; READ: rectum adenocarcinoma; SARC: sarcoma; SKCM: skin cutaneous melanoma; STAD: stomach adenocarcinoma; TGCT: testicular germ cell tumor; THCA: thyroid carcinoma; THYM: thymoma; UCEC: uterine corpus endometrial carcinoma; UCS: uterine carcinosarcoma; UVM: uveal melanoma. ; ; ; ns not significant.
(a) |
(b) |
(c) |
(d) |
(e) |
(f) |
(g) |
(h) |
(i) |